Relay Therapeutics, INC Form 4 insider transactions

Director Jami Rubin exercised stock options for 42,242 shares of Relay Therapeutics common stock at a price of $5.04 per share on June 10, 2024.

Mark Murcko, a director at Relay Therapeutics, reported the acquisition of stock options for 102,225 shares on June 3, 2024.

Director Laura Shawver of Relay Therapeutics, Inc. was granted stock options for 102,225 shares on June 3, 2024.

Director Jami Rubin of Relay Therapeutics, Inc. reports the acquisition of stock options for 102,225 shares on June 3, 2024.

Director Sekar Kathiresan of Relay Therapeutics, Inc. reports the acquisition of stock options on June 3, 2024.

Director Douglas Ingram acquired stock options for 102,225 shares of Relay Therapeutics common stock on June 3, 2024.

Director Alexis Borisy of Relay Therapeutics, Inc. acquired stock options for 102,225 shares on June 3, 2024.

Director Linda Hill reports receiving a stock option for 102,225 shares of Relay Therapeutics common stock on June 3, 2024.

Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, sold shares to cover tax obligations and under a pre-arranged 10b5-1 trading plan.

Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, sold 1,345 shares of common stock to cover income tax withholding obligations upon the vesting of restricted stock units.

Brian Adams, Chief Legal Officer of Relay Therapeutics, sold 1,623 shares of common stock on April 29, 2024, to cover income tax withholding obligations upon the vesting of restricted stock units.

Thomas Catinazzo, CFO of Relay Therapeutics, sold 1,695 shares of common stock on April 29, 2024, to cover income tax withholding obligations upon the vesting of restricted stock units.

Donald A. Bergstrom, President of R&D at Relay Therapeutics, sold shares to cover income tax withholding obligations upon the vesting of restricted stock units.

Thomas Catinazzo, CFO of Relay Therapeutics, sold 348 shares of common stock to cover income tax withholding obligations upon the vesting of restricted stock units.

Donald A. Bergstrom, President of R&D at Relay Therapeutics, sold 765 shares of common stock to cover income tax withholding obligations upon the vesting of restricted stock units.

Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, sold 298 shares of common stock on March 27, 2024, to cover income tax withholding obligations upon the vesting of restricted stock units.

Brian Adams, Chief Legal Officer of Relay Therapeutics, sold 348 shares of common stock on March 27, 2024, to cover income tax withholding obligations upon the vesting of restricted stock units.